Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

ATTITUDE Bathroom Cleaner Disinfectant

Canada Type III Ongoing · initiated 2026-07-20

Labelling. Discontinue use if you have the affected product.Contact the recalling firm if you have any questions about the recall.Report any health product safe…

Supernova and Supreme Nicotine Film and Pouches

Canada Type II Ongoing · initiated 2026-07-15

Unauthorized product. Only use authorized nicotine replacement therapies as directed.Do not buy or use unauthorized nicotine replacement therapies. If you becom…

Apo-Tiotropium 18 mcg Capsules

Canada Type II Ongoing · initiated 2026-07-13

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Oribe Serene Scalp Densifying Shampoo

Canada Type II Ongoing · initiated 2026-07-13

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

BD ChloraPrep™ Clear - 1mL Applicator

Canada Type II Ongoing · initiated 2026-07-13

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

JAMP Chlorthalidone 12.5 mg Tablets

Canada Type III Ongoing · initiated 2026-07-06

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health conce…

Fludeoxyglucose (18F) Injection

Canada Type III Ongoing · initiated 2026-07-02

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-06-29

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-06-29

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-06-29

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Lannett Company Inc.

US Class II Ongoing · initiated 2026-06-26

Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

Remifentanil hydrochloride for injection 1 mg/vial

Canada Type II Ongoing · initiated 2026-06-26

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Spiriva 18mcg capsule

Canada Type III Ongoing · initiated 2026-06-25

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Reliance Life Sciences Private Limited

US Class II Ongoing · initiated 2026-06-24

Lack of Sterility Assurance

Reliance Life Sciences Private Limited

US Class II Ongoing · initiated 2026-06-24

Lack of Sterility Assurance

Reliance Life Sciences Private Limited

US Class II Ongoing · initiated 2026-06-24

Lack of Sterility Assurance

Reliance Life Sciences Private Limited

US Class II Ongoing · initiated 2026-06-24

Lack of Sterility Assurance

QuVa Pharma, Inc.

US Class II Ongoing · initiated 2026-06-24

Failed Impurities/Degradation Specifications

Lupin Pharmaceuticals Inc.

US Not Yet Classified Ongoing · initiated 2026-06-23

CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing.

Direct Rx

US Class II Ongoing · initiated 2026-06-22

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2026-06-17

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Polyflex 25 g/vial powder for suspension

Canada Type II Ongoing · initiated 2026-06-17

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

The Harvard Drug Group LLC

US Class II Ongoing · initiated 2026-06-16

Subpotent Drug

Lancora 5 mg tablet

Canada Type III Ongoing · initiated 2026-06-16

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Par Health USA, LLC

US Class II Ongoing · initiated 2026-06-12

Crystallization; identified as Buprenorphine free base